
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is seeing growth in its pharmaceutical sales, with a notable increase of 8% in the second quarter. Despite facing competitive headwinds in the glucagon generic market, the company's overall sales were bolstered by strong demand for generic epinephrine products and an additional $1.9M in sales from supplier shortages. While the discontinuation of one product at its IMS facility may have a slight impact, it is not expected to significantly affect the company's financials. Additionally, the company has a diverse geographic presence and a focus on developing challenging generic and proprietary products, providing potential for long-term growth and success.
Bears say
Amphastar Pharma is facing several headwinds including pricing challenges for their Baqsimi product, declines in sales for their injectable glucagon product, and potential competitive risks for their generic products. Additionally, there are no major catalysts expected in the near-term, leading to concerns about the company's ability to drive top-line growth. Furthermore, the recent launch of its ipratropium bromide HFA product may not provide significant revenue growth in the short term, and risks associated with potential competitors could add further pressure to the company's growth prospects. The lack of positive developments and potential risks in the coming years leads to a negative outlook for Amphastar Pharma's stock.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares